Portfolio Grader currently ranks Novo Nordisk A/S (NYSE:NVO) a Hold. The approach to investing incorporated in this analytical tool developed by Louis Navellier researches and ranks nearly 5,000 stocks each week from a fundamental and quantitative perspective. The current Portfolio Grader recommendation on the shares has been in place for the last month. More
NVO
Recent Articles
Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock Soars on New CEO News
Teva Pharmaceutical (TEVA) stock was flying high today following news of a new CEO that will be joining the company soon. More
10 Biotech Stocks With Game-Changing Dates in Q3
If you're looking to speculate in the inherent volatility of biotech stocks, here are ten impending events that could cause those fireworks. More
5 Reasons Why VIVUS, Inc. (VVUS) Stock Should Be in Your Portfolio
VIVUS is a biopharmaceutical company developing and commercializing innovative, next-generation therapies. Here's why VVUS stock is a must More
Global Blood Therapeutics Inc (GBT) Stock Soars on Takeover Talk
Global Blood Therapeutics (GBT) stock is rising as the company is being targeted for a takeover by another pharma corporation. Here's what's happenig More
9 Top Pharmaceutical Stocks to Buy for the Dividends
Fans of dividends don't have to completely abandon all hope for growth too -- these top pharmaceutical stocks offer the best of both worlds. More
3 European Stocks to Buy for Big-Time Dividends
Don't overlook European stocks when it comes to dividends. Companies like Diageo (DEO), Novo Nordisk (NVO) and Eni (E) are stellar. More
